GANX 10-Q: SEC filing
Gain Therapeutics
Filed with the SEC on · accession 0001104659-26-125167
GANX filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -0.9% by the first close after the filing.
Summary of the filing
Gain Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and ongoing operations.
Key details
How GANX stock reacted
Close before
$1.09
Nov 9, 2026
First close after
-0.92%
$1.08
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for GANX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for GANX?
Click hereFrequently asked questions
What did GANX file with the SEC on Nov 10, 2026?
GANX filed a 10-Q (SEC filing). Gain Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and ongoing operations.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did GANX stock react to this filing?
GANX closed at $1.09 before the filing and $1.08 on Nov 10, 2026 (-0.92%).
Other GANX SEC filings
Get alerts when GANX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days